[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": [
            "MALT1 inhibitor"
        ],
        "dcp_id": null,
        "interventional_model": "SEQUENTIAL_ASSIGNMENT",
        "lead_org": "Monopteros Therapeutics Inc.",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Has a histologically- or cytologically-diagnosed solid tumor which is advanced or metastatic and which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists. Subject's prior treatment should include all approved regimens that have demonstrated a survival advantage for the subject's disease, stage, and line of therapy."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Is aged \u226518 years at the time of signing the ICF"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Has provided written informed consent"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Has an ECOG Performance Status of 0 or 1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "Has measurable disease per RECIST 1.1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Has an adequate tumor sample."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "Has adequate liver, renal, hematologic, pulmonary, cardiac, and coagulation function."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "Has a negative serum pregnancy test (for women of child-bearing potential) at Screening and a negative urine pregnancy test on Day 1 prior to the first dose of MPT 0118"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "Ability to swallow and retain and absorb oral medications in tablet or crushed form orally or via feeding tube (e.g., nasogastric feeding tube or percutaneous endoscopic gastrostomy feeding tube)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 9,
                    "description": "Has received cytotoxic chemotherapy, biologic agent, investigational agent, checkpoint inhibitors, or radiation therapy \u22643 weeks prior to the first dose of MPT-0118"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 10,
                    "description": "Has received small-molecule kinase inhibitors or hormonal agents \u226414 days prior to the first dose of MPT-0118"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 11,
                    "description": "Has been previously treated with a MALT1 inhibitor"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 12,
                    "description": "Has clinically significant AEs that have not returned to baseline or \u2264Grade 1 based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 13,
                    "description": "Has received systemic immunosuppressive agents within 14 days of the first dose of MPT-0118"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 14,
                    "description": "Has undergone major surgery \u22646 weeks or minor surgery \u226414 days prior to the first dose of MPT-0118"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 15,
                    "description": "Has clinically significant intercurrent disease"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 16,
                    "description": "Part B and Part C: Has previously been treated with PD-1, PD-L1, or CTLA-4 inhibitors and required dose-interruption, permanent discontinuation, or systemic immunosuppression due to immune-related AEs"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 17,
                    "description": "Has primary central nervous system (CNS) tumors or brain or leptomeningeal metastasis."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 18,
                    "description": "Has human immunodeficiency virus (HIV) infection"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 19,
                    "description": "Has active hepatitis B or C infection"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 20,
                    "description": "Women who are pregnant or breastfeeding"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 21,
                    "description": "Has an unwillingness or inability to comply with procedures required in this protocol"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 22,
                    "description": "Is currently receiving any other anticancer or investigational agent"
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": "MPT-0118 will be administered orally twice daily (BID). Pembrolizumab will be administered\r\n      intravenously (IV) at a dose of 200 mg every 3 weeks.",
        "official_title": "A Phase 1/1b Study of MPT-0118 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Refractory Solid Tumors",
        "_phase_sort_order": 4,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Through study completion, an average of 1 year",
                "name": "Part A and B: DoR based on RECIST v 1.1 and iRECIST",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "1 cycle / 28 days",
                "name": "Part A and B: Maximum plasma concentration of MPT-0118",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Through study completion, an average of 1 year",
                "name": "Part A and B: ORR based on RECIST v 1.1 and iRECIST",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Through study completion, an average of 1 year",
                "name": "Part A and B: PFS based on RECIST v 1.1 and iRECIST",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "1 cycle / 28 days",
                "name": "Part A: To determine the MTD or the RP2D of MPT-0118",
                "description": "The incidence and severity of treatment-emergent adverse events (TEAEs) qualifying as protocol-defined DLTs in Cycle 1 will guide the establishment of the protocol-defined RP2D and/or MTD.",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "1 cycle / 28 days",
                "name": "Part B: To determine the MTD or the RP2D of MPT-0118 + pembrolizumab",
                "description": "The incidence and severity of TEAEs qualifying as protocol-defined DLTs in Cycle 1 will guide the establishment of the protocol-defined RP2D and/or MTD.",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Through study completion, an average of 1 year",
                "name": "Part C: Assessment of Overall Survival",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Through study completion, an average of 1 year",
                "name": "Part C: Duration of response (DoR) based on RECIST v1.1 and iRECIST",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Through study completion, an average of 1 year",
                "name": "Part C: Number of subjects with TEAEs as assessed by NCI-CTCAE v5.0",
                "description": "Incidence of TEAEs will be used to assess the safety of MPT-0118 + pembrolizumab",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Through study completion, an average of 1 year",
                "name": "Part C: Objective response rate (ORR) based on RECIST v1.1 and iRECIST",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Through study completion, an average of 1 year",
                "name": "Part C: Progression-free survival (PFS) based on RECIST v1.1 and iRECIST",
                "description": null,
                "type_code": "PRIMARY"
            }
        ],
        "phase": "I",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 3,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT04859777",
        "biomarkers": [],
        "classification_code": null,
        "current_trial_status_date": "2021-04-13",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Cancer",
                    "resistant cancer",
                    "clinical resistance"
                ],
                "nci_thesaurus_concept_id": "C120186",
                "name": "Refractory Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C7628"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Cancer"
                ],
                "nci_thesaurus_concept_id": "C9270",
                "name": "Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Tumor",
                    "Tumor, secondary",
                    "Neoplasm, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor, metastatic",
                    "Metastatic Tumor",
                    "Neoplasm, metastatic",
                    "Metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Tumor, malignant, NOS",
                    "Malignancy",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease",
                    "Malignant Growth",
                    "CA",
                    "Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Diseases",
                    "Disease",
                    "Diseases and Disorders",
                    "disease_term",
                    "Diagnosis",
                    "Disease or Disorder, Non-Neoplastic",
                    "disease type",
                    "Disorders",
                    "Disease or Disorder",
                    "Disorder",
                    "condition",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Cancer",
                    "Secondary Malignancy"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36255",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm",
                    "Neoplasms, NOS",
                    "tumor",
                    "Neoplastic Growth",
                    "Tumor, NOS",
                    "Neoplasia",
                    "Neoplasm, NOS",
                    "Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Tumor"
                ],
                "nci_thesaurus_concept_id": "C7628",
                "name": "Refractory Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "MPT-0118-101",
        "active_sites_count": 3,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-PD-1 Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C128037",
                        "name": "Anti-PD1 Monoclonal Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C124946",
                            "C20401"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C143250",
                        "name": "Immune Checkpoint Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C141144"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastics",
                            "Anti-Cancer Agents",
                            "Antineoplastic Drugs",
                            "Antiproliferative Agents",
                            "Tumor-Specific Treatment Agents",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Anti-Tumor Agents",
                            "Antiproliferative Drugs",
                            "Cancer Drug",
                            "Anti-Tumor Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Monoclonal Antibodies",
                            "Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C20401",
                        "name": "Monoclonal Antibody Therapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immune Mediators",
                            "Immune Modulators",
                            "Immunopotentiators",
                            "Immunomodulatory Agent",
                            "Immunotherapy Agent",
                            "Immunotherapeutic Agent",
                            "Immune Regulators",
                            "BRM",
                            "Biomodulators",
                            "Immunomodulators",
                            "Immunomodulating Agent",
                            "Biological Response Modifier"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Programmed Cell Death Protein 1 Inhibitor",
                            "Anti-PD-1 Agent",
                            "PD-1-targeting Agent",
                            "PD-1 Inhibitor",
                            "Protein PD-1 Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C124946",
                        "name": "PD1 Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C163758",
                            "C143250"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Molecularly Targeted Therapy Agent",
                            "Anti-tumor Targeted Therapy Agent",
                            "Targeted Agent",
                            "Targeted Therapeutic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C163758",
                        "name": "Targeted Therapy Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug Substance",
                            "Pharmaceutical Agent",
                            "Pharmaceuticals",
                            "Drug",
                            "Pharmacologic Agent",
                            "Pharmacological Substance",
                            "Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug Substance",
                            "Pharmaceutical Agent",
                            "Pharmaceuticals",
                            "Drug",
                            "Pharmacologic Agent",
                            "Pharmacological Substance",
                            "Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Keytruda"
                        ],
                        "nci_thesaurus_concept_id": "C106432",
                        "name": "Pembrolizumab",
                        "description": "A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C128037"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C141144",
                        "name": "Immune Checkpoint Modulator",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Biopharmaceuticals",
                            "Immunologic, Immunochemical",
                            "Immunologics",
                            "Biological Products",
                            "Biologicals",
                            "Biologics"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Part A:",
                "description": "Dose-escalation oral MPT-0118 BID",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Part B:",
                "description": "Dose-escalation oral MPT-0118 BID + pembrolizumab (IV)",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Part C:",
                "description": "Dose-expansion oral MPT-0118 BID + pembrolizumab (IV)",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2021-05846",
        "why_study_stopped": null,
        "brief_summary": "This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID\r\n      (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid\r\n      tumors.\r\n\r\n      The study will be conducted in 3 parts:\r\n\r\n        -  Part A: MPT-0118 dose-escalation\r\n\r\n        -  Part B: MPT-0118 dose-escalation in combination with pembrolizumab\r\n\r\n        -  Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab",
        "brief_title": "A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors",
        "status_history": [
            {
                "status_date": "2021-04-13T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 70,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 0,
        "start_date": "2021-04-13",
        "record_verification_date": "2021-08-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": null,
        "nci_programs": [],
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2023-03-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]